Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...